Alkem Laboratories Ltd. AI Stock Analysis
Want to see IN:ALKEM full AI Analyst Report?
Alkem Laboratories Ltd. (ALKEM) AI Stock Analysis
Alkem Laboratories Ltd.
(NSE:ALKEM)
The score is primarily driven by strong financial performance (steady growth, solid profitability, and low leverage), partially offset by weaker cash conversion. Technical indicators are currently bearish/soft (below key moving averages with negative MACD), and valuation support is limited given the ~29.7 P/E and ~1% dividend yield.
Alkem Laboratories Ltd. (ALKEM) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 613.07B
- Dividend Yield
- 1.03%
- Average Volume (3M)
- 14.56K
- Price to Earnings (P/E)
- 29.8
- Beta (1Y)
- 0.53
- Revenue Growth
- 12.54%
- EPS Growth
- -12.62%
- Country
- India
- Employees
- 19,346
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Alkem Laboratories Ltd. Business Overview & Revenue Model
Company Description
Alkem Laboratories Ltd. functions as a pharmaceutical enterprise, engaged in the research, manufacturing, and worldwide distribution of both medicinal and nutritional products. Its comprehensive offerings encompass a variety of branded and generic dr...
How the Company Makes Money
Alkem makes money primarily by selling pharmaceutical products, with revenues driven by (1) domestic sales in India and (2) international sales through exports and overseas market presence. Its core revenue model is product-led: it manufactures finis...
Alkem Laboratories Ltd. Financial Statement Overview
Summary
Strong overall fundamentals supported by steady revenue expansion, solid profitability, and a conservatively positioned balance sheet with low leverage and healthy (though moderating) ROE. The main offset is weaker cash conversion, with free cash flow not consistently keeping pace with net income.
Income Statement
78PositiveBalance Sheet
82Very PositiveCash Flow
70Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 150.81B | 147.12B | 128.05B | 124.39B | 114.40B | 105.12B |
| Gross Profit | 90.49B | 96.19B | 79.47B | 74.07B | 64.58B | 62.29B |
| EBITDA | 32.91B | 34.14B | 29.71B | 24.18B | 17.09B | 21.89B |
| Net Income | 21.57B | 23.02B | 21.65B | 17.96B | 9.84B | 16.46B |
Balance Sheet | ||||||
| Total Assets | 0 | 208.73B | 176.91B | 155.75B | 137.57B | 140.69B |
| Cash, Cash Equivalents and Short-Term Investments | 40.61B | 40.65B | 37.78B | 42.70B | 11.43B | 13.13B |
| Total Debt | 0 | 20.47B | 13.81B | 14.18B | 13.97B | 26.68B |
| Total Liabilities | -143.49B | 65.24B | 52.57B | 48.60B | 43.22B | 52.22B |
| Stockholders Equity | 143.49B | 138.20B | 119.85B | 103.12B | 90.45B | 86.38B |
Cash Flow | ||||||
| Free Cash Flow | 4.40B | 13.46B | 12.37B | 16.89B | 14.50B | 7.72B |
| Operating Cash Flow | 8.37B | 19.63B | 19.13B | 19.48B | 16.82B | 11.11B |
| Investing Cash Flow | -15.68B | -16.67B | -12.99B | -10.09B | 1.13B | -14.35B |
| Financing Cash Flow | 4.63B | -5.03B | -8.11B | -11.45B | -17.61B | 3.80B |
Alkem Laboratories Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALKEM, the sentiment is Negative. The current price of 5145.00 is below the 20-day moving average (MA) of 5164.64, below the 50-day MA of 5196.02, and below the 200-day MA of 5395.98, indicating a bearish trend. The MACD of 4.35 indicates Positive momentum. The RSI at 47.16 is Neutral, neither overbought nor oversold. The STOCH value of 19.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALKEM.
Alkem Laboratories Ltd. Peers Comparison
Overall Rating
IN:AUROPHARMA80Outperform
IN:TORNTPHARM69Neutral
IN:MANKIND67Neutral
IN:ALKEM66Neutral
IN:SUNPHARMA64Neutral
IN:DRREDDY63Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | INR 1.04T | 26.18 | ― | 0.39% | 13.53% | 17.04% | |
| 69Neutral | INR 1.76T | 75.54 | ― | 0.32% | 42.06% | -3.48% | |
| 67Neutral | INR 1.09T | 48.39 | ― | 0.04% | 13.27% | 27.32% | |
| 66Neutral | INR 615.16B | 29.82 | ― | 1.03% | 12.54% | -12.62% | |
| 64Neutral | INR 4.57T | 41.58 | ― | 0.84% | 12.13% | 4.94% | |
| 63Neutral | INR 1.17T | 41.69 | ― | 0.57% | -3.60% | -52.23% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ALKEM | Alkem Laboratories Ltd. | 5145.00 | -500.70 | -8.87% | |
| IN:AUROPHARMA | Aurobindo Pharma Ltd | 1807.00 | 606.26 | 50.49% | |
| IN:DRREDDY | Dr. Reddy's Laboratories Ltd. | 1398.00 | 161.29 | 13.04% | |
| IN:MANKIND | Mankind Pharma Ltd. | 2630.00 | 387.00 | 17.25% | |
| IN:SUNPHARMA | Sun Pharmaceutical Industries Limited | 1903.00 | 139.31 | 7.90% | |
| IN:TORNTPHARM | Torrent Pharmaceuticals Ltd | 4616.00 | 958.74 | 26.21% |
Alkem Laboratories Ltd. Corporate Events
Alkem Laboratories Incorporates Saudi Arabian Pharmaceutical Joint Venture
Alkem Laboratories, a pharmaceutical company focused on medicines and nutraceutical products, has incorporated Alkem Pharma Company, a limited liability joint venture in Saudi Arabia. The venture broadens the company’s international market focus and...
Alkem Orders Forensic Audit After Alleged Employee Fund Misuse
Alkem Laboratories Ltd. has initiated a forensic audit after detecting a recent incident involving alleged misappropriation of funds by a former employee, as approved by its Audit Committee on October 21, 2026. The move reflects the company’s effort...
Alkem Laboratories Strengthens Leadership With Senior Management Appointment
Alkem Laboratories has appointed Dr. Shubhadeep Sinha to a senior management role effective September 15, 2026, strengthening its leadership team. Dr. Sinha brings over 25 years of experience across clinical development, medical affairs, pharmacovigi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 29, 2026
